Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol. 2007

Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
Laboratory of Neuropsychopharmacology, Division of Life Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.

BACKGROUND Although chronic use of methamphetamine (METH) leads to long-lasting cognitive dysfunction in humans, there are few reports about an animal model that reflects METH-induced impairment of working memory. OBJECTIVE In this study, we investigated the effect of repeated METH treatment on spatial working memory in rats. METHODS Rats were repeatedly administered METH (2 mg/kg) once a day for 7 days, and their memory function was assessed with a delayed spatial win-shift task in a radial arm maze. The task consisted of two phases, a training phase and a test phase, separated by a delay. RESULTS METH-treated animals showed an impairment of performance in the test phase when the delay time was increased from 5 to 30 min or longer. The effect of METH persisted for at least 14 days after the drug withdrawal. METH-induced impairment of working memory was reversed by clozapine (3 and 10 mg/kg, for 7 days), but not haloperidol (1 and 2 mg/kg, for 7 days). The improving effect of clozapine diminished 7 days after the withdrawal. Phosphorylated extracellular signal-regulated kinase1/2 (ERK1/2) levels were significantly increased in the hippocampus of saline-treated control rats from 5 to 60 min after the training phase. In contrast, hyperphosphorylation of ERK1/2 was abolished in the hippocampus of rats treated with METH. CONCLUSIONS These findings suggest that repeated METH treatment induces impairment of working memory, which is associated with a dysfunctional ERK1/2 pathway in the hippocampus. Furthermore, clozapine may be effective for the treatment of METH-induced cognitive dysfunction.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D008694 Methamphetamine A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed. Deoxyephedrine,Desoxyephedrine,Desoxyn,Madrine,Metamfetamine,Methamphetamine Hydrochloride,Methylamphetamine,N-Methylamphetamine,Hydrochloride, Methamphetamine,N Methylamphetamine
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums

Related Publications

Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
July 2008, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
June 2009, Journal of sleep research,
Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
June 2009, Progress in neuro-psychopharmacology & biological psychiatry,
Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
September 2010, The international journal of neuropsychopharmacology,
Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
July 2008, Perception & psychophysics,
Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
January 2011, Vision research,
Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
August 2012, Neuroscience research,
Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
May 1993, Pharmacology, biochemistry, and behavior,
Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
September 1994, Psychopharmacology,
Taku Nagai, and Kazuhiro Takuma, and Misato Dohniwa, and Daisuke Ibi, and Hiroyuki Mizoguchi, and Hiroyuki Kamei, and Toshitaka Nabeshima, and Kiyofumi Yamada
February 2003, Behavioural brain research,
Copied contents to your clipboard!